Metabolic shift underlies tumor progression and immune evasion in S‐nitrosoglutathione reductase‐deficient cancer
The Journal of Pathology · 2023
DOI: 10.1002/path.6080 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pathology, 2023. Verfasst von Rafael Mena-Osuna und 16 weiteren Autor:innen. Beteiligte Einrichtung: Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain. Hauptthemen laut MEDLINE: Oxidoreductases, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministerio de Ciencia e Innovación, Universidad de Córdoba.
Abstract (Originalsprache)
S‐nitrosoglutathione reductase (GSNOR) is a denitrosylase enzyme that has been suggested to play a tumor suppressor role, although the mechanisms responsible are still largely unclear. In this study, we show that GSNOR deficiency in tumors is associated with poor prognostic histopathological features and poor survival in patients with colorectal cancer (CRC). GSNOR‐low tumors were characterized by an immunosuppressive microenvironment with exclusion of cytotoxic CD8 + T cells. Notably, GSNOR‐low tumors exhibited an immune evasive proteomic signature along with an altered energy metabolism characterized by impaired oxidative phosphorylation (OXPHOS) and energetic dependence on glycolytic activity. CRISPR‐Cas9‐mediated generation of GSNOR gene knockout (KO) CRC cells confirmed in vitro and in vivo that GSNOR‐deficiency conferred higher tumorigenic and tumor‐initiating capacities. Moreover, GSNOR‐KO cells possessed enhanced immune evasive properties and resistance to immunotherapy, as revealed following xenografting them into humanized mouse models. Importantly, GSNOR‐KO cells were characterized by a metabolic shift from OXPHOS to glycolysis to produce energy, as indicated by increased lactate secretion, higher sensitivity to 2‐deoxyglucose (2DG), and a fragmented mitochondrial network. Real‐time metabolic analysis revealed that GSNOR‐KO cells operated close to their maximal glycolytic rate, as a compensation for lower OXPHOS levels, explaining their higher sensitivity to 2DG. Remarkably, this higher susceptibility to glycolysis inhibition with 2DG was validated in patient‐derived xenografts and organoids from clinical GSNOR‐low tumors. In conclusion, our data support the idea that metabolic reprogramming induced by GSNOR deficiency is an important mechanism for tumor progression and immune evasion in CRC and that the metabolic vulnerabilities associated with the deficiency of this denitrosylase can be exploited therapeutically. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain.
- Cancer Network Biomedical Research Centre (CIBERONC), Madrid, Spain.
- Department of Medicine, Faculty of Medicine, University of Córdoba, Córdoba, Spain.
- Department of Genetics, University of Córdoba, Córdoba, Spain.
- Medical Oncology Department, Reina Sofía University Hospital, Córdoba, Spain.
- Immunology Department, Reina Sofia University Hospital, Córdoba, Spain.
ORCID-Profile: Silvia Guil-Luna, Antonio Rodríguez-Ariza
Förderung
- Ministerio de Ciencia e Innovación
- Universidad de Córdoba
Zitieren
APA
Mena-Osuna, R., Mantrana, A., Guil-Luna, S., Sánchez-Montero, M. T., Navarrete-Sirvent, C., Morales-Ruiz, T., Rivas-Crespo, A., Toledano-Fonseca, M., García-Ortíz, M. V., García-Jurado, G., Gómez-España, M. A., González-Fernández, R., Villar, C., Medina-Fernández, F. J., Villalba, J. M., Aranda, E., & Rodríguez-Ariza, A. (2023). Metabolic shift underlies tumor progression and immune evasion in S‐nitrosoglutathione reductase‐deficient cancer. The Journal of Pathology. https://doi.org/10.1002/path.6080
Vancouver
Mena-Osuna R, Mantrana A, Guil-Luna S, Sánchez-Montero MT, Navarrete-Sirvent C, Morales-Ruiz T, et al. Metabolic shift underlies tumor progression and immune evasion in S‐nitrosoglutathione reductase‐deficient cancer. The Journal of Pathology. 2023. doi:10.1002/path.6080
BibTeX
@article{MenaOsuna2023,
author = {Mena-Osuna, Rafael and Mantrana, Ana and Guil-Luna, Silvia and Sánchez-Montero, María Teresa and Navarrete-Sirvent, Carmen and Morales-Ruiz, Teresa and Rivas-Crespo, Aurora and Toledano-Fonseca, Marta and García-Ortíz, María Victoria and García-Jurado, Gema and Gómez-España, María Auxiliadora and González-Fernández, Rafael and Villar, Carlos and Medina-Fernández, Francisco Javier and Villalba, José Manuel and Aranda, Enrique and Rodríguez-Ariza, Antonio},
title = {Metabolic shift underlies tumor progression and immune evasion in S‐nitrosoglutathione reductase‐deficient cancer},
journal = {The Journal of Pathology},
year = {2023},
doi = {10.1002/path.6080}
}
EUVIMED